New drug combo shows promise against tough leukemia
NCT ID NCT05306301
First seen Mar 16, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This study tests a new combination treatment for adults aged 18-65 with a specific, high-risk type of acute lymphoblastic leukemia (ALL) called BCR/ABL1-like. The treatment adds the targeted drug ponatinib to standard chemotherapy. The goal is to see if this approach can make the cancer disappear more quickly and deeply, as measured by minimal residual disease (MRD) after three cycles.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, ACUTE LYMPHOBLASTIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dipartimento di Medicina Traslazionale e di Precisione - Ematologia
Roma, Italy
-
Ematologi Presidio Ospedaliero Guglielmo da Saliceto
Piacenza, Italy
-
Ematologia AO Ospedali Riuniti Villa Sofia Cervello
Palermo, Italy
-
Ematologia AOU Careggi
Florence, Italy
-
Ematologia AOU Federico II
Naples, Italy
-
Ematologia AOU Maggiore della Carità
Novara, Italy
-
Ematologia AOU Policlinico Tor Vergata
Roma, Italy
-
Ematologia AOU Policlinico Vittorio Emanuele-Ferrarotto
Catania, Italy
-
Ematologia AOU S.ORSOLA-MALPIGHI
Bologna, Italy
-
Ematologia AOU Senese
Siena, Italy
-
Ematologia ASST Papa Giovanni XXIII
Bergamo, Italy
-
Ematologia ASST Spedali Civili
Brescia, Italy
-
Ematologia Fondazione Policlinico San Matteo
Pavia, Italy
-
Ematologia Ospedale Maggiore Policlinico
Milan, Italy
-
Ematologia Ospedale Mauriziano
Torino, Italy
-
Ematologia Ospedale S.Giovanni Battista Molinette
Torino, Italy
-
Ematologia Ospedale V.Fazzi
Lecce, Italy
-
Ematologia Ospedale dell'Angelo
Mestre, Italy
-
Ematologia Policlinico A.Gemelli
Roma, Italy
-
Ematologia Policlinico G.B. Rossi
Verona, Italy
-
Ematologia Presidio Ospedaliero Infermi
Rimini, Italy
-
Ematologia Presidio Ospedaliero Spirito Santo
Pescara, Italy
-
Ematologia Presidio Ospedaliero Tortora
Pagani, SA, Italy
-
Ematologia con Unità di Trapianto
Avellino, AV, 83100, Italy
Conditions
Explore the condition pages connected to this study.